Skip to main content
European Commission logo print header

Coiled-coil mediated exonuclease tethering technology for the enhancement of CRISPR gene editing

Project description

CRISPR gene-editing enhancement by coiled-coil mediated exonuclease tethering technology

CRISPR technology represents a milestone for life science and biotechnology, as it can be used to modify the genomes of virtually all organisms. Selected genes can be easily inactivated, and this is one of its key applications for cell-based therapy and industrial biotechnology. Boosting the efficiency of this technology could have immense value and impact. The goal of the EU-funded CCedit project is to enhance Cas9/CRISPR technology and establish its innovation potential. Recently, project researchers designed Cas9 DNA targeting and cleavage complex tethering to the ExoIII exonuclease via an engineered coiled-coil dimer, which strongly improved inactivation of target genes. Specific objectives of the current project are to refine the CCedit technology, establish its implementation and viability within the framework of Cas9/CRISPR technology, and develop business plan and commercialisation strategies.

Objective

The discovery and implementation of CRISPR technology represents a milestone for biotechnology and life sciences in general as the genomes of virtually all organisms can be modified by this technology and have already resulted in billions of euros of added value. With this technique, selected genes can be rather easily inactivated (knock out), which is one of the key applications of CRISPR for cell-based therapy and industrial biotechnology. Any improvement of the efficiency of CRISPR therefore has very high value and potential impact. Recently we designed Cas9 DNA targeting and cleavage complex to be tethered to the ExoIII exonuclease via an engineered coiled-coil (CC) dimer, developed in the ERC AdG project MaCChines. We found that it strongly improved inactivation of target genes, even better than direct genetic fusion of Cas9-ExoIII. Since this invention has a substantial translation potential we recently filed a patent application (priority number EP19192490).
The strategic frontier of CCedit is to maximise the value of this enhancement of Cas9/CRISPR technology and establish the innovation potential arising from the ERC project MaCChines in the pre-demonstration phase.
Specific objectives are to:
• Refine the components of the CCedit technology and its implementation for specific applications;
• Establish technological viability and its placement within the framework of Cas9/CRISPR technology;
• Demonstrate and select most promising implementations of this technology for applications;
• Investigate the IP, FTO and policy regulations landscape and further develop the IP portfolio;
• Develop the business plan and commercialisation strategy for the technology;
• Disseminate information on this technology and raise the interest of companies and other potential users of this technology and obtain links to early stage funding.
• Train members of the project team and local community on entrepreneurial skills in biotech

æ

Coordinator

KEMIJSKI INSTITUT
Net EU contribution
€ 150 000,00
Address
Hajdrihova 19
1000 Ljubljana
Slovenia

See on map

Region
Slovenija Zahodna Slovenija Osrednjeslovenska
Activity type
Research Organisations
Links
EU contribution
No data

Beneficiaries (1)